







Time to order patient materials?

Simply fill out and fax to 1-800-241-0436

- | | | | | | |
|--------------------------|---|--|--------------------------|---|---|
| <input type="checkbox"/> |  | Spring Counter Card
(1 counter card) Item: APC01UN10 | <input type="checkbox"/> |  | Exam Room HDSS Tear Pad
(1 tear pad) Item: APC22EH09 |
| <input type="checkbox"/> |  | Waiting Room Tent Card (Wedding)
(1 tent card) Item: APC21YO10 | <input type="checkbox"/> |  | Reconstitution and Iodine Starch Test Information Sheet
(1 sheet) Item: APC93IB09 |
| <input type="checkbox"/> |  | Patient Brochure
(20 brochures) Item: APC89ZD09 | <input type="checkbox"/> |  | Prescribing Information With Medication Guide
(1 guide) Item: APC48MX09 |

What other information or materials would you or your patients find useful? _____

Name: _____ Position: _____

Practice name: _____

Address: _____

City/State/Zip Code: _____

Phone: _____ E-mail: _____

FAX TO 1-800-241-0436 or **E-MAIL** your request to cmrfulfillment@consolidated.com and include the information listed above. Please allow 5 to 7 business days for delivery. Thank you.

The name of my Allergan representative is _____ (optional)

- Yes, please notify me about training programs for my staff on severe underarm sweating inadequately managed with topical agents.
- I no longer wish to receive materials from Allergan, Inc., about BOTOX[®] (onabotulinumtoxinA) for severe underarm sweating inadequately managed with topical agents.

Indication

BOTOX[®] is indicated for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.

IMPORTANT SAFETY INFORMATION

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of BOTOX[®] and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses.

Please see additional Important Safety Information on reverse side.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

BOTOX[®] is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS

The recommended dosage and frequency of administration for BOTOX[®] should not be exceeded. Risks resulting from administration at higher dosages are not known.

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of BOTOX[®] are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX[®] cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect

Postmarketing safety data from BOTOX[®] and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death related to spread of toxin effects. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, and particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia.

No definitive, serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX[®] at the labeled dose of 100 Units (for severe primary axillary hyperhidrosis) have been reported.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, urticaria, soft tissue edema, and dyspnea.

Pre-Existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of BOTOX[®].

ADVERSE REACTIONS

General

There have been spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin.

There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.

Primary Axillary Hyperhidrosis

The most frequently reported adverse events (3% to 10% of patients) following injection of BOTOX[®] for severe primary axillary hyperhidrosis include injection-site pain and hemorrhage, nonaxillary sweating, infection, pharyngitis, flu syndrome, headache, fever, neck or back pain, pruritus, and anxiety.

Overdosage

Excessive doses of BOTOX[®] may be expected to produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. In the event of overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis.

In the event of suspected or actual overdosage, please contact your local or state health department to process a request for antitoxin through the Centers for Disease Control and Prevention (CDC). If you do not receive a response within 30 minutes, please contact the CDC directly at 1-770-488-7100.

Please see accompanying full prescribing information including the Medication Guide.